SCHEMBL4397008

SCHEMBL4397008

NC(=O)N1CCC1C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.42
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSD11B1 P28845 5/20 0.35
EPHX1 P07099 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
SLC18A3 Q16572 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
DPP4 P27487 3/20 0.33
FAP Q12884 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
CNR2 P34972 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449743 0.92 DPP7 (0.50) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL4449748 0.92 DPP7 (0.50) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL23842585 0.90 NPC1 (0.45) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL2125244 0.90 NPC1 (0.45) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL23842831 0.90 NPC1 (0.45) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL938422 0.88 NPC1 (0.50) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL30057505 0.82 DPP4 (0.37) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL14740663 0.78 NPC1 (0.45) DPP7NPC1RAB9ASMN1; SMN2POLB
SCHEMBL2383924 0.78 KDM4E (0.37) DPP7NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL30291716 0.75 DPP4 (0.43) NPC1RAB9ASMN1; SMN2POLBSLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620395-B1 AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS VERNALIS RES LTD (GB) 2009-12-30 EP disclosed
EP-1620395-A1 AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS VERNALIS RESEARCH LIMITED (GB) 2006-02-01 EP disclosed
WO-2004096763-A1 AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS VERNALIS RESEARCH LIMITED (GB) 2004-11-11 WO disclosed